Engineered yeast cells can mimic real cancer cells and be used to test new cancer immunotherapies much faster, benefiting patients.

The American Federation for Aging Research (AFAR) is pleased to announce the release of silverlinings.bio, an interactive report and simulation tool developed by AFAR Scholar-in-Residence Raiany Romanni-Klein, PhD. At silverlinings.bio, users can input their own timelines and assumptions for specific scientific breakthroughs in aging biology, then see the ROI in terms of US lives saved & GDP growth.

For years, drug companies and industry allies have argued that the U.S. gets faster and wider access because its government moves quicker than foreign regulators, but the new analysis suggests the U.S. advantage in drug access is driven less by faster government review and more by when companies apply for review and the type of drugs they submit.

The use of medicines to address mental health or behavioral conditions climbed from 2001 until 2020, analysis showed, but the increase has led to safety concerns 

Ambient artificial intelligence tools that capture clinician-patient conversations and generate draft clinical notes are now widely used in U.S. hospitals but unevenly adopted, according to a new nationwide study from researchers at Emory University's Rollins School of Public Health.

Breast cancer (BC) is the most common cancer and the second leading cause of cancer death in women. It is a highly variable disease, defined as a malignancy of the epithelial ducts in breast tissue. Characterizing the vast heterogeneity within BC cells and their surrounding tumor microenvironment is crucial because this diversity is the primary reason for treatment resistance, disease progression and poor patient prognosis.

 

In a new study from Boston University Chobanian & Avedisian School of Medicine, researchers assembled a comprehensive single-cell atlas of the human breast, combining data from 138 patients and more than 600,000 single cells. They then were able to identify cell populations and cell states that previously were unclear or missed and linked these cell types to tumor features (like subtype and grade) and patient outcomes.  

The ACMG Foundation for Genetic and Genomic Medicine (ACMGF) is pleased to announce that Bo Yuan, PhD, FACMG, has been selected as the recipient of the 2026 Dr. Michael S. Watson Genetic and Genomic Medicine Innovation Award, an honor recognizing exceptional innovation that advances the field of genetic and genomic medicine. The award is named for Michael S. Watson, MS, PhD, FACMG, the American College of Medical Genetics and Genomics’ first and longstanding Executive Director, whose leadership helped shape modern clinical genomics.